Welcome to our dedicated page for Vtv Therapeutics news (Ticker: VTVT), a resource for investors and traders seeking the latest updates and insights on Vtv Therapeutics stock.
vTv Therapeutics Inc. reports developments as a late-stage biopharmaceutical company focused on oral, small-molecule drug candidates for diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a liver-selective glucokinase activator being investigated as an oral adjunctive therapy to insulin for type 1 diabetes. Company updates also reference development work and partnerships across additional chronic-disease candidates, including the PDE4 inhibitor HPP737.
Recurring announcements include clinical and regulatory updates for cadisegliatin, financial results and corporate updates, license and collaboration activity, investor-conference participation, and Nasdaq inducement grants under equity compensation plans. News about vTv often connects pipeline progress with funding arrangements, intellectual property, and business-development agreements that support its drug-development strategy.
vTv Therapeutics (Nasdaq: VTVT) reported Q1 2026 revenue of $36.8 million and net income attributable to shareholders of $24.1 million, or $1.94 basic and $1.65 diluted EPS.
Cash and equivalents were $98.1 million, supported by a $20 million upfront payment from a Newsoara license amendment. Phase 3 CATT1 enrollment for cadisegliatin in type 1 diabetes remains on track to complete in Q3 2026, with cash expected to fund operations through topline data.
vTv Therapeutics (Nasdaq: VTVT) granted 39,500 stock options as material inducements to two non-executive employees under Nasdaq Listing Rule 5635(c)(4).
The options carry a weighted average exercise price of $32.00 per share, vest over four years (25% after one year, then quarterly over 36 months), have a 10-year term, and are governed by the 2026 Inducement Plan and individual option agreements.
vTv Therapeutics (Nasdaq: VTVT) said management will attend two investor conferences in May 2026: H.C. Wainwright BioConnect in New York on May 19, 2026 and Alliance Global Partners Healthcare Company Showcase (virtual) on May 20, 2026.
Live fireside chat webcasts and replays will be available on the company website's Media & Events section.
vTv Therapeutics (Nasdaq: VTVT) granted 4,000 stock options to a non-executive employee as a material inducement under Nasdaq Listing Rule 5635(c)(4).
The options carry an exercise price of $39.54 (closing price on April 6, 2026), 10-year term, and vest over four years (25% at one year, then quarterly over 36 months), subject to the 2026 Inducement Plan and the stock option agreement.
vTv Therapeutics (Nasdaq: VTVT) said its management team will participate in a fireside chat and hold 1x1 investor meetings at the 38th Annual ROTH Conference in Dana Point, CA, March 22-24, 2026.
The fireside chat is scheduled for March 23, 2026 at 10:00 AM PDT and will be webcast live with a replay available on the company website.
vTv Therapeutics (Nasdaq: VTVT) reported Q4 and full-year 2025 results and provided a corporate update on March 10, 2026. Cash was $88.9M at year-end; the company received $20.0M upfront from Newsoara in Feb 2026 under an amended license for HPP737. Enrollment in the Phase 3 CATT1 trial is expected to complete in Q3 2026.
Full-year 2025 net loss was $27.0M ($3.20 per share); R&D spend rose to $17.9M driven by cadisegliatin clinical activity.
vTv Therapeutics (Nasdaq: VTVT) said management will participate in two investor conferences in late February and early March 2026. Events: Oppenheimer 36th Annual Healthcare Life Sciences Conference (Feb 26, 2026, 11:20 AM ET, virtual, presentation only) and TD Cowen 46th Annual Health Care Conference (Mar 3, 2026, 9:50 AM ET, Boston, presentation and 1x1 meetings). Webcasts will be available for both events per the company.
vTv Therapeutics (Nasdaq: VTVT) amended its license with Newsoara to grant an exclusive worldwide license to develop and commercialize PDE4 inhibitor HPP737. vTv will receive a $20 million upfront payment, up to ~$50 million in development milestones, up to $65 million in sales milestones, and tiered royalties.
vTv continues to advance cadisegliatin in its ongoing Phase 3 CATT1 trial while leveraging the Newsoara collaboration to monetize and de-risk HPP737 globally.
vTv Therapeutics (Nasdaq: VTVT) submitted a Phase 2 clinical study protocol for cadisegliatin to the Abu Dhabi Department of Health in collaboration with M42’s IROS.
The double-blind, randomized, placebo-controlled trial will be the longest cadisegliatin study to date: a 12-month trial enrolling approximately 300 insulin-treated type 2 diabetes patients across UAE, Jordan, and Tunisia, with three arms (400 mg once daily, 800 mg once daily, and placebo). The first patient first visit is expected in Q1 2026. vTv is the regulatory sponsor and M42 is funding the study.
vTv Therapeutics (Nasdaq: VTVT) reported Q3 2025 results and operational updates on Nov 6, 2025. Key developments include randomizing the first patient in the Phase 3 CATT1 trial (Aug 2025) and expecting topline CATT1 data in H2 2026. The company completed an $80 million private placement (Sep 2025) to fund CATT1 and program development. Cash was $98.5 million at September 30, 2025 versus $36.7 million at December 31, 2024. R&D expense for Q3 2025 was $7.0 million (Q3 2024: $3.2M); G&A was $3.7 million (Q3 2024: $3.3M). Q3 net loss attributable to vTv shareholders was $8.7 million or $1.08 per basic share. A U.S. patent covering crystalline salts and co-crystals of cadisegliatin was allowed with exclusivity expected through 2041.